Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer

Medical Oncology

Volumn 24, Issue 4, 2007, Pages 407-412

  Albertsson, M ^a   Johansson, B ^b   Friesland, S ^a   Kadar, L ^c   Letocha, H ^d   Frykholm, G ^e   Wagenius, G ^f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adenocarcinoma; Chemotherapy; Docetaxel; Esophageal; Esophageal cancer; Gemcitabine; Metastatic; Squamous cell carcinoma

Indexed keywords

BETAMETHASONE; DOCETAXEL; GEMCITABINE;

ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 36248982096     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0028-6     Document Type: Article

References (23)

1. Mantravadi R, Lad T, Briele H, Liebner EJ. Carcinoma of the esophagus: sites of failure. Int J Radiat Oncol Biol Phys 1982;8(11):1897-1901.
2. Mandard AM et al. Autopsy findings in 111 cases of esofhageal cancer. Cancer 1981;48:329-35.
3. Anderson L, Lad T. Autopsy findings in squamous cell carcinoma of the esophagus. Cancer 1982;50:1587-90.
4. Attah E, Hadju S. Benign and malignant tumors of the esophagus at autopsy. J Thoracic Cardiovasc surg 1968;55(3):396-404.
5. Bosch A, Frias Z, Caldwell W, Jaeschke WH. Autopsy findings in carcinoma of the esophagus. Acta Radiol Oncol 1979;18:103-12.
6. Roth JA, Putman SB, Rich TA, Forastiere AA. In: De Vita V Jr. Hellman S, Rosenber S, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott, 1997;980-1021.
7. Bleiberg H, Conroy T, Paillot B et al. Randomized phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-20.
8. Salts L, Kelson D. Combined modality therapy in the treatment of locoregional oesophageal cancer. Ann Oncol 1992;3:793-9.
9. Iizuka T et al. Phase II study of CDDP + 5-FU for squamous esophageal carcinoma. JEOG cooperative study results. Proc Am Soc Clin Oncol 1991;10:157.
10. Rigas JR, Dragnev KH, Bubis JA. Docetaxel in the treatment of esophageal cancer. Semin Oncol 2005;32(2 Suppl 4):S39-51.
11. Safran H et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004;22(5):670-7.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
13. Ajani JA et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Nat Cancer Inst 1994;86:1086-91.
14. Muro K et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15(6):955-9.
15. Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancer. Cancer Invest 2003;21(6):887-96.
16. Kulke MH et al. A phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest 2006;24(4):346-50.
17. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal and esophageal cancers. Cancer 2006;107(2):221-31.
18. Enzinger PC et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005;50(12):2218-23.
19. Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004;16(14 suppl 14):22-5.
20. Pozzo C et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004;15(12):177-81.
21. Airoldi M et al. Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 2003;20(1):19-24.
22. Wittes RE, Adrianza ME, Parsons R et al. Compilation of phase II results with single antineoplastic agents. Cancer Treat Symp 1985;4:91-130.
23. Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with Cisplatin and 5-fluorouracil. Radiother Oncol 1988;13(1):41-6.